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Abstract
ATP6L, the C subunit of the V-ATPase V0 domain, is involved in regulating the acidic 
tumor micro-environment and may promote tumor progression. However, the ex-
pression and functional role of ATP6L in tumors have not yet been well explored. 
In this study, we found that ATP6L protein overexpression was related to colorec-
tal cancer histological differentiation (P < 0.001), presence of metastasis (P < 0.001) 
and recurrence (P = 0.02). ATP6L expression in the liver metastatic foci was higher 
than in the primary foci (P = 0.04). ATP6L expression was notably concomitant with 
epithelial-mesenchymal transition (EMT) immunohistochemical features, such as re-
duced expression of the epithelial marker E-cadherin (P = 0.021) and increased ex-
pression of the mesenchymal marker vimentin (P = 0.004). Results of in vitro and in 
vivo experiments showed that ATP6L expression could alter cell morphology, regu-
late EMT-associated protein expression, and enhance migration and invasion. The 
effect of ATP6L on metastasis was further demonstrated in a tail vein injection mice 
model. In addition, the mouse xenograft model showed that ATP6L-overexpressing 
HCT116 cells grew into larger tumor masses, showed less necrosis and formed more 
micro-vessels than the control cells. Taken together, our results suggest that ATP6L 
promotes metastasis of colorectal cancer by inducing EMT and angiogenesis, and is a 
potential target for tumor therapy.
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1  | INTRODUC TION
Colorectal carcinoma (CRC) is the third most common cancer world-
wide.1 The incidence and mortality rate of CRC are rapidly increasing, 
especially in developing countries.2 According to 2015 cancer statis-
tics, the incidence of CRC will increase by 60% by 2030.1 Despite the 
overall increase in the survival of CRC patients due to chemotherapy 
and targeted therapy over the past two decades, metastasis remains 
the major obstacle in CRC treatment and prognosis.2,3
Paget first proposed the “seed and soil” theory, emphasizing the 
importance of the tumor microenvironment (TME) with hypoxia, 
elevated interstitial fluid pressure, low glucose level and acidic ex-
tracellular pH.4,5 Extensive evidence has shown that the interaction 
between tumor cells and TME contributes to the malignant progres-
sion of tumor cells; therefore, studies on the molecular mechanisms 
underlying TME may help people to develop more effective treat-
ment modalities.6 One of the hallmarks of TME is the existence of an 
unusual acidic microenvironment. Most malignant lesions produce 
energy by glycolysis at a vastly higher rate than normal tissues even 
in oxygenated environments; this process is known as the Warburg 
effect.7 Coupled with abnormal blood perfusion, the infinite prolif-
eration cycle of cancer cells sharply increases oxygen consumption 
and leads to the accumulation of lactic acid, the product of glycol-
ysis, thereby creating a high acid load in tumor tissues.7 Acidic gra-
dients are toxic to normal cells because cellular acidosis is a trigger 
for apoptosis.8 In contrast, low extracellular pH confers multiple 
advantages to the process of tumorigenesis and metastasis by pro-
moting cancer cell proliferation, degrading the extracellular matrix, 
suppressing the host immune system and promoting angiogene-
sis.8-10 Clinical investigations have shown that acidic environments 
are associated with increased mutation rate, enhanced metastatic 
incidence and poor prognosis of patients with malignant tumors.11,12 
In addition, anticancer agents are usually sensitive to pH alteration. 
Acidic environments may reduce the uptake and cytotoxicity of an-
ticancer agents, further aiding tumor chemoresistance.13 To stay 
alive, cancer cells must pump excess protons into the extracellu-
lar environment and maintain a relatively neutral intracellular pH. 
Vacuolar H+-ATPase (V-ATPase) uses the energy produced by ATP 
hydrolysis to pump protons into the lumina of acidic vacuoles or to 
the extracellular environment.14 Accumulating clinical evidence has 
revealed that V-ATPase is overexpressed in various types of cancers, 
including melanoma, prostate, breast and pancreatic cancer cells.15-
18 V-ATPase has been implicated in many aspects of tumor develop-
ment, particularly in the proliferation, resistance to apoptosis and 
senescence of cancer stem cells (CSC) and invasion and metasta-
sis.14 ATP6L, the C subunit of the V-ATPase V0 domain, presents in 
multiple copies per V-ATPase, making it the most critical subunit of 
V-ATPase.19 This subunit is highly hydrophobic and responsible for 
transmembrane proton transport.14 ATP6L expression is markedly 
increased in pancreatic cancer and hepatocellular carcinoma.15,20 
However, the expression and functional role of ATP6L in other types 
of cancer is still poorly understood.
In this study, the clinicopathological significance of ATP6L and 
the correlation between ATP6L expression and EMT immunohisto-
chemical features were analyzed in tissue specimens from 193 col-
orectal cancer patients. The expression of ATP6L was also detected 
in 20 sets of matched CRC primary foci and liver metastatic foci. The 
effects of ATP6L expression in HT29 and HCT116 cells on the ex-
pression of epithelial and mesenchymal markers and EMT transcrip-
tion factors were detected. The proliferation, migration and invasion 
in cell cultures and a mouse xenograft model with ATP6L overex-
pression were investigated. A tail vein injection mice model was 
established to investigate metastasis promoting effect of ATP6L. In 
addition, the effects of the ectopic expression of ATP6L in colorectal 
cancer cell line HCT116 on the EMT-associated proteins and angio-
genesis in an animal xenograft model were studied.
2  | MATERIAL S AND METHODS
2.1 | Clinical samples
We collected 193 formalin-fixed, paraffin-embedded colorectal 
cancer tissue samples and 20 sets of matched CRC primary foci and 
liver metastatic foci from Tianjin Medical University Cancer Institute 
and Hospital (Tianjin, China) from January 2002 to December 2004. 
None of the patients had received any chemotherapy or radiother-
apy before their operation. Data of clinicopathological parameters 
were obtained from patients’ clinical records and pathological re-
ports. All the samples underwent a uniform protocol for fixation/
dissection. All sections were evaluated by two senior pathologists. 
The use of the tissue samples in this study was approved by the 
Institutional Research Committee.
2.2 | Cell culture reagents and animals
The human colorectal cancer cell lines HCT116 and HT29 were 
obtained from the Cell Resource Center at the Institute of Basic 
Medical Sciences, Chinese Academy of Medical Sciences/Peking 
Union Medical College (Beijing, China). HCT116 cell lines were cul-
tured in Iscove modified Dulbecco medium with 10% FBS. HT29 
cells were cultured in DMEM with 5% FBS. Both cell lines were 
cultured at 37°C in 5% CO2 incubator. ATP6L recombinant protein 
K E Y W O R D S
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was obtained from R&D Systems. The micro-Boyden chambers 
used were from NeuroProbe. Antibodies to ATP6L, Snail, Slug and 
Twist were from Abcam. The antibody to E-cadharin was from 
BD Biosciences. The antibody to vimentin was from Epitomics. 
Phalloidin was from Invitrogen. The antibody to CD34 was from 
Santa Cruz Biotechnology. Alexa Fluor 488 was from Molecular 
Probes. BALB/C nude mice (4-5 weeks old) were obtained from Wei 
Tong Li Hua Experimental Animal Company.
2.3 | Immunohistochemical staining
Streptavidin-biotin-peroxidase staining was performed as previ-
ously described.21 In a typical procedure, the sections were pre-
treated with microwaves, blocked and incubated with a series of 
antibodies overnight at 4°C. Then, they were immunostained with 
HRP-conjugated antibody and signals were revealed, with 3,3-diam-
inobenzidine buffer used as substrate. In place of primary antibodies 
for the negative control, PBS was used.
The expression of ATP6L, E-cadherin and vimentin was analyzed 
only histologically in normal and neoplastic epithelial cells and not 
in stromal tissues. ATP6L staining was considered immunoreactive 
when brown granules were identified in the cytoplasm. The staining 
intensity of ATP6L was graded on a scale from 0 to 2 (0 for no stain-
ing, 1 for weak immunoreactivity and 2 for strong immunoreactiv-
ity). Percentage immunoreactivity was scored on a scale from 0 to 3 
(0 for <10% of cells being positive, 1 for <30% of cells being positive, 
2 for 30%–60% of cells being positive and 3 for >50% of cells being 
positive). We multiplied the two scores to obtain a composite ATP6L 
expression score. ATP6L expression was classified as negative (−) 
(score = 0), weakly positive (+) score = (1, 2, or 3) or strongly positive 
(++) (score = 4, 5 or 6). E-cadherin expression was considered to be 
positive if >90% of cancer cells exhibited a staining pattern similar to 
that in normal epithelial cells. Vimentin expression was classified as 
positive when >10% tumor cells were stained.
2.4 | Plasmid transfection
Transfection with plasmid carrying ATP6L (forward primer 
5′-ACCCGAATTCATGTCCGAGTCCAAGAGCGGC-3′, reverse 
primer 5′-CGGACTCGAGCTACTTTGTGGAGAGGATGAG-3′) ATP6L 
siRNA (5′-CGCCCTCATCCTCTCCACAAA-3′) and controlled scram-
bled plasmid (Genechem) was performed with Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions. To estab-
lish stable HCT116 and HT29 cells that overexpressed ATP6L, G418-
resistant cells were screened.
2.5 | Western blot analysis
Protein (30-50 μg/lane) was separated by 10% SDS-PAGE and trans-
ferred to polyvinylidene difluoride membranes. Blots were blocked 
and incubated with primary antibodies overnight at 4°C, incubated 
with secondary antibody, and detected with ECL western blot sub-
strate (Millipore) according to the manufacturer’s instructions.
2.6 | Cell proliferation assay
Cells were separately seeded into 96-well plates at 1 × 103/well and 
incubated for different periods (1, 2, 3, 4 or 5 days). After 4 hours of 
incubation at 37°C, MTT (Sigma-Aldrich) solution was added. The 
purple crystals were dissolved by DMSO. The optical density was 
determined at 490 nm using a Spectra Max M2 (Molecular Devices).
2.7 | Migration/invasion assay
Cell motility was examined in a transwell assay using 24-well plates 
with uncoated inserts (8-μm pore, BD Biosciences) to examine mi-
gration or Matrigel-coated inserts to assess invasiveness. Briefly, 
200 μL of cell suspension (5 × 105 cells/mL) contained in serum-free 
medium was added to the upper part, and 300 μL of culture medium 
supplemented with 20% FBS was added to the lower chamber. After 
incubation at 37°C with 5% CO2 for 24 hours, the cells were fixed 
and stained. The entire membrane was counted by light microscopy 
in six random fields.
2.8 | Immunofluorescence confocal microscopy
Cells were cultured on sterile glass cover slips on the day before 
staining. Cells were fixed with 4% paraformaldehyde, quenched with 
50 mmol/L NH4Cl, permeabilized in 0.2% Triton X-100, and blocked 
in 3% BSA. The slips were incubated with the primary antibodies 
overnight at 4°C, labeled with the specific secondary antibodies for 
1 hour in the dark, mounted, and visualized with a confocal laser 
scanning microscope (Leica TCS SP5, Leica Microsystems).
2.9 | In vivo assay
To generate murine subcutaneous tumors, 20 mice were randomly 
and evenly divided into two groups and given either 3 × 106 control 
or HCT116 cells overexpressing ATP6L by subcutaneous injection in 
the right groin. Tumor size was measured every 5 days for 30 days. 
Tumor volumes were calculated using the following formula: vol-
ume = (length [in millimeters] × width2 [in square millimeters])/2. 
To generate lung metastasis models, the control and HCT116 cells 
overexpressing ATP6L cells (10 mice/group, 3 × 106/mL; 0.15 mL per 
mice) were injected into the tail vein. After 3 weeks, the mice were 
killed, and viscera (lung, liver, kidney and spleen) were harvested. 
Tumor samples or harvested viscera tissue were formalin-fixed and 
paraffin-embedded. The tissues were then subjected to H&E and im-
munohistochemical staining.
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2.10 | H&E staining and the evaluation of the non–
necrosis area and microvessel density
H&E staining was performed to examine the necrosis of the tumor 
mass of xenograft mice. Tissue samples were sectioned (thickness, 
4 μm) and deparaffinized in xylene. Tissue sections were stained with 
H&E, cleared in xylene and mounted on slides using neutral balsam. 
The photos were captured using the software Image-Pro Plus (Media 
Cybernetics). Based on the different color of the necrotic and non–
necrotic areas, the software calculated the level of non–necrosis (as a 
percentage of the total area relative to the entire histological section). 
The results were presented as mean and SD. Microvessel density 
(MVD) was determined by immunohistochemical staining of CD34. 
Ten separate areas with the highest density of discrete microvessels 
within each section were selected for vessel quantification at ×200 
magnification. The results were presented as mean and SD.
F I G U R E  1   Expression of ATP6L by 
immunohistochemical staining in human 
colorectal carcinoma (CRC) tissue samples 
and in matched CRC primary foci and 
liver metastatic foci. A, Representative 
CRC samples with ATP6L negative 
(left), weak (middle) and strong (right) 
expression, 400×. Strong expression of 
ATP6L was observed in (B) invasive front 
and (C) liver metastatic foci, 200×. IHC, 
Immunohistochemical staining
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Variable Total
ATP6L expression n (%)
χ2 P-value− + ++
Age
<45 26 6 (23.1) 12 (46.2) 8 (30.8) 2.380 0.304
≥45 167 20 (12.0) 89 (53.3) 58 (34.7)
Sex
Male 88 10 (11.4) 45 (51.1) 33 (37.5) 1.094 0.579
Female 105 16 (15.2) 56 (53.3) 33 (31.4)
Size
<5 cm 134 19 (14.2) 70 (52.2) 45 (33.6) 0.212 0.899
≥5 cm 59 7 (11.9) 31 (52.5) 21 (35.6)
Differentiation
Well 14 4 (28.6) 8 (57.1) 2 (14.3) 33.343 <0.001*
Mediate 95 14 (14.7) 64 (67.4) 17 (17.9)
Poor 84 8 (9.5) 29 (34.5) 47 (56.0)
Clinical stage
I 7 1 (14.3) 4 (57.1) 2 (28.6) 8.480 0.205
II 124 19 (15.3) 71 (57.3) 34 (27.4)
III 51 5 (9.8) 22 (43.1) 24 (47.1)
IV 11 1 (9.1) 4 (36.4) 6 (54.5)
Metastasis
Present 66 6 (9.1) 25 (37.9) 35 (53.0) 15.835 <0.001*
Absent 127 20 (15.7) 76 (59.8) 31 (24.4)
Recurrence
Present 10 3 (30.0) 1 (10.0) 6 (60.0) 7.803 0.020*
Absent 183 23 (12.6) 100 (54.6) 60 (32.8)
*Significantly different (P < 0.05). 
TA B L E  1   Correlation between ATP6L 
and clinicopathologic characteristics of 
colorectal cancer
 
ATP6L expression n (%)
χ2 P valueTotal − + ++
Primary foci 20 1 (5.0) 11 (55.0) 8 (40.0) 6.433 0.040*
Metastatic foci 20 0 (0.0) 4 (20.0) 16 (80.0)   
Total 40 1 (2.5) 15 (75.0) 24 (52.5)   
*Significantly different. 
TA B L E  2   ATP6L expression in matched 
colorectal cancer primary foci and 
metastatic foci in liver
 
ATP6L expression n (%)
χ2 P-valueTotal − + ++
E-cadherin
Absent 16 0 (0.0) 5 (31.3) 11 (68.8) 7.768 0.021*
Present 187 26 (13.9) 96 (51.3) 55 (29.4)
Vimentin
Absent 187 26 (13.9) 98 (52.4) 53 (28.3) 11.179 0.004*
Present 16 0 (0.0) 3 (18.8) 13 (81.3)
*Significantly different. 
TA B L E  3   Correlation between 
expression of ATP6L and E-cadherin and 
vimentin
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2.11 | Statistical analysis
SPSS v.16.0 software (SPSS, Chicago, IL, USA) was used for data 
analysis. The associations between ATP6L and clinicopathologic pa-
rameters and the differential expression of E-cadherin and vimentin 
between different ATP6L expression-level groups were assessed 
with Fisher’s exact test and the χ2 test. Differences or correlations 
between groups were assessed using the Mann-Whitney U test, 
Student’s t test and Pearson’s correlation test. Significance was set 
at P < 0.05.
3  | RESULTS
3.1 | Association of ATP6L expression with clinico-
pathological features of colorectal carcinoma 
A total of 167 (86.5%) patients showed positive ATP6L expression, 
whereas the remaining 26 (13.5%) showed negative ATP6L expres-
sion. Tumors were categorized as strong (++), weak (+) or negative 
(−) for ATP6L expression (Figure 1A). The relationship of ATP6L 
level in CRC with each clinicopathological parameter was analyzed 
(Table 1). ATP6L expression level in CRC increases as differentiation 
grade decreases. Positive ATP6L expression was observed in 10 of 
14 (71.4%) well-differentiated patient samples, in 81 of 95 (85.3%) 
moderately differentiated patient samples and 76 of 84 (90.5%) 
poorly differentiated patient samples. ATP6L was strongly ex-
pressed in samples with the presence of metastasis and recurrence. 
A total of 66 (34.2%) patients experienced metastasis. Patients with 
strong ATP6L expression had a higher rate of metastasis (35/66, 
53.0%) than those with weak (25/66, 37.9%) or negative ATP6L ex-
pression (6/66, 9.1%). Strong ATP6L expression was detected in 6 
of 10 (60%) colorectal cancer specimens from patients that experi-
enced recurrence and in 60 of 183 (32.8%) specimens from patients 
that did not experience recurrence. Significant correlation between 
ATP6L expression and gender, age, tumor size or clinical stage were 
not observed.
Differences in ATP6L expression levels within tumors were 
found. Tumor cells close to the adjacent interstitial component 
showed higher ATP6L expression than those at the cancer center 
(Figure 1B).
ATP6L expression was also analyzed in the 20 sets of matched 
specimens (including primary foci and liver metastatic foci) obtained 
from each patient. Table 2 and Figure 1C show the upregulated 
ATP6L expression in liver metastatic foci as compared with that in 
the primary cancer in each patient. These data indicate that ATP6L is 
involved in tumor progression in CRC.
3.2 | ATP6L expression is concomitant with epithelial-
mesenchymal transition immunohistochemical features
To assess the relationship between ATP6L and EMT in CRC, we in-
vestigated the expression of the EMT-associated markers E-cadherin 
and vimentin. As shown in Table 3 and Figure 2, the ATP6L-negative/
weak expression group showed higher E-cadherin expression and 
lower vimentin expression than the group with ATP6L strong expres-
sion. The expression of ATP6L was correlated with the expression of 
E-cadherin (P = 0.021) and vimentin (P = 0.004) (Table 3). These find-
ings confirm the role of ATP6L in activating the EMT program.
F I G U R E  2   Expression of ATP6L is concomitant with epithelial-mesenchymal transition (EMT) immunohistochemical features in human 
colorectal carcinoma (CRC) tissue samples. E-cadherin expression was higher in ATP6L negative (−) or weak expression (+) samples than in 
strong-expression (++) samples. Tumor cells in the ATP6L (−)/(+) samples did not express vimentin, whereas some tumor cells in the ATP6L 
(++) samples expressed vimentin
F I G U R E  3   ATP6L expression induced a mesenchymal phenotype and changed the morphology of HCT116 and HT29 cells. A, 
Immunofluorescent staining of E-cadherin and vimentin. A green signal represents staining for the corresponding protein, while a blue signal 
represents nuclear DNA staining by DAPI. Scale bar: 50 μm. B, Expression of epithelial-mesenchymal transition (EMT) regulatory proteins, 
including E-cadherin, vimentin, Snail, Slug and Twist, were examined by immunoblotting. C, Cell morphology was analyzed by confocal laser 
scanning microscopy according to the immunolocalization of F-actin. Scale bar: 25 μm
     |  483WANG et Al.
484  |     WANG et Al.
3.3 | ATP6L overexpression induces epithelial-
mesenchymal transition and changes the 
morphology of HCT116 and HT29 cells
We established ATP6L-overexpressed and ATP6L knockdown 
HCT116 and HT29 cells to study the EMT-promoting effect of 
ATP6L on CRC. The EMT process refers to a molecular transition 
with the decreased expression of the epithelial marker E-cadherin 
and increased expression of the mesenchymal markers, such as vi-
mentin. Western blot and immunofluorescence assays demonstrated 
that both HCT116 and HT29 cells with ATP6L overexpression had 
decreased expression of E-cadherin and increased expression of 
vimentin compared with control cells, while cells with downregu-
lated ATP6L had increased expression of E-cadherin and decreased 
expression of vimentin compared with control cells (Figure 3A,B). 
In addition to classical EMT markers, we examined the expression 
of a set of EMT transcription factors, namely, Snail, Slug and Twist, 
which can repress E-cadherin expression by binding to the E-boxes of 
E-cadherin promoter directly. Among them, Snail was upregulated in 
both HCT116 and HT29 cells that overexpressed ATP6L, whereas the 
expression levels of Slug showed no significant change (Figure 3B). 
Twist was upregulated in ATP6L-overexpressed HCT 116 cells, but its 
expression in ATP6L-overexpressed HT29 cells showed no obvious 
change (Figure 3B). Expression of Snail and Twist was decreased in 
both the ATP6L knockdown HCT116 and HT29 cells, whereas the 
expression levels of Slug showed no significant change (Figure 3B).
We also observed alterations in cellular morphology and func-
tional phenotypes other than in epithelial and mesenchymal protein 
expression. A portion of the cytoskeleton was observed by using 
phalloidin to dye fibrous actin (F-actin). This observation revealed 
that ATP6L overexpression caused HCT116 and HT29 cells to exhibit 
a scattered, spindle, mesenchymal-like shape, whereas control cells 
showed a tightly, uniform, cuboid-like appearance (Figure 3C). As we 
expected, knockdown of ATP6L resulted in restoration of epithelial 
phenotypes (Figure 3C). These findings suggested that cells over-
expressing ATP6L are susceptible to mesenchymal differentiation.
3.4 | ATP6L expression promotes migration and 
invasion ability of HCT116 and HT29 cells in vivo
The proliferation rate of cells with either increased or decreased 
ATP6L expression showed no significant differences from that of 
control cells when an MTT assay was used (Figure 4A). During the 
EMT process, polarized epithelial cells reorganize the cytoskel-
eton, resolve the cell-cell junction and cell-ECM interaction, which 
F I G U R E  4   Effect of ATP6L expression 
on proliferation, migration and invasion 
ability of HCT116 and HT29 cells. A, MTT 
assay showed no significant differences 
between the proliferation rate of 
ATP6L-overexpressed cells and control 
cells. B and C, Transwell assays showing 
migration/invasion of cells. Cells invading 
through uncoated inserts and Matrigel-
coated inserts were stained, 400×. 
*P < 0.05
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are accompanied by increased invasiveness and metastasis.22 
Migration and invasion assays revealed that more cells overexpress-
ing ATP6L passed through the transwell membrane than control 
cells (Figure 4B,C, HCT116: migration: 33.0 ± 8.75 vs 17.6 ± 4.72, 
t = 3.654, P = 0.001; invasion:34.6 ± 6.88 vs 20.4 ± 4.88, t = 3.766, 
P = 0.0078; HT29: migration: 33.0 ± 5.54 vs 21.2 ± 1.58, t = 4.579, 
P = 0.007; invasion: 37.8 + 5.83 vs 25 ± 3.49, t = 4.211, P = 0.005), 
whereas downregulation of ATP6L expression suppressed the mi-
gration and invasion abilities of HCT116 and HT29 cells, respectively 
(Figure 4B,C, HCT116: migration: 22.0 ± 1.58 vs 11.6 ± 0.92, t = 5.674, 
P = 0.0005; invasion:16.0 ± 2.47 vs 9.2 ± 1.02, t = 2.545, P = 0.0345; 
HT29: migration: 27.0 ± 2.92 vs 17.0 ± 2.03, t = 2.817, P = 0.0226; 
invasion: 18.0 ± 1.58 vs 12.0 ± 1.58, t = 2.683, P = 0.0278). Our 
findings suggest that ATP6L expression increased the migratory, in-
vasive and metastatic potential of HCT116 and HT29 cells.
3.5 | Overexpression of ATP6L promotes tumor 
growth and metastasis of HCT116 cells in vivo
In agreement with in vitro analyses, HCT116 cells with overexpressed 
levels of ATP6L grew into larger tumor masses, as shown in Figure 5A,B 
(Day 25:310 ± 81 mm3 vs 186 ± 45 mm3, t = 2.702, P = 0.027; Day 
30:400 ± 49.4 mm3 vs 220 ± 29.5 mm3, t = 3.138, P = 0.0138). Among 
the 10 mice injected with ATP6L-overexpressed HCT116 cells, 1 
showed tumor invasion into the surrounding adipose tissue and another 
exhibited the formation of intravascular tumor thrombus, whereas 
no metastasis sites were detected in mice injected with control cells 
(Figure 5C). We further established lung metastasis mouse models 
by tail vein injection and found that ATP6L overexpressing HCT116 
cells formed more lung metastatic nodules (Figure 5D, 1.6 ± 0.43 vs 
0.5 ± 0.22, t = 2.283, P = 0.0348). To assess the EMT activity in xeno-
grafts, we performed E-cadherin and vimentin immunohistochemical 
staining on the sections of the xenograft tissues. The respective de-
crease of E-cadherin and increase of vimentin expression levels were 
observed in ATP6L tumors, as shown in Figure 5E.
3.6 | ATP6L expression is correlated with decreased 
necrotic area and increased microvessel density in the 
sections of xenograft tissues
H&E photographs illustrate a decrease in the percentage of the ne-
crotic area in mice tumor tissues derived from ATP6L-transfected 
F I G U R E  5   Effect of ATP6L expression 
on tumor growth, metastasis and 
epithelial-mesenchymal transition (EMT) 
in vivo. A, Photograph of representative 
tumors from mice injected with control 
or ATP6L-transfected HCT116 cells. B, 
ATP6L-overexpressing cells produced 
larger tumor masses than control cells. 
C, H&E staining of adipose tissue and 
intravascular thrombus, 200×. D, H&E 
staining of lung tissues of tail vein injected 
mice, 40×. E, Immunohistochemical 
staining of ATP6L, E-cadherin and 
vimentin expression in harvested mouse 
tumor samples, 200×. *P < 0.05
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HCT116 cells (Figure 6A,B, 4.07 ± 4.88% vs 21.9 ± 10.03%, t = 2.22, 
P = 0.045). MVD counts were higher in the tumor sections of 
HCT116 cells with overexpressed ATP6L than those in the control 
cases (Figure 6C, 13.7 ± 1.14 vs 18.1 ± 1.64, t = 2.209, P = 0.0404). 
These results indicate the angiogenesis-promoting effect of ATP6L 
on CRC.
4  | DISCUSSION
ATP6L has an array of functions in physical as well as pathological 
processes. The overexpression of ATP6L enhances the invasion ac-
tivity of fibroblasts and inhibits integrin β1-mediated HEK293 cell 
motility through the glycosylation of integrin β1.23,24 ATP6L has a 
protective role against sodium nitroprusside-induced autophagic ap-
optosis through inhibition of c-Jun N-terminal kinase (JNK) and p38 
in glutathione-depleted glial cells.25 However, only a few previous 
literature mention the correlation between ATP6L expression and 
tumor progression. Xu et al20 reported that the messenger RNA and 
gene expression levels of ATP6L in human hepatocellular carcinoma 
tissues were markedly increased compared with those in normal liver 
tissues. Ohta et al15 reported that increased ATP6L expression cor-
relates with increasing invasive potential in pancreatic cancer, and 
Cotter et al26 showed that the inhibition of ATP6L activity reduces 
invasion and migration of breast cancer cells in vitro. Here, we ini-
tially analyzed ATP6L expression in a large array of colorectal cancer 
tissues and observed that the correlation of ATP6L expression with 
histological differentiation, metastasis and recurrence was signifi-
cant. In addition, ATP6L expression in the liver metastasis foci was 
markedly higher than that in colorectal primary foci. These results 
indicate the possible role of ATP6L in inducing CRC progression.
The EMT phenomenon refers to the conversion of epithelial 
cells into mesenchymal phenotype cells.27 In the EMT process, ep-
ithelial cancer cells lose their apical-basal polarity and cell-cell and 
cell-ECM adhesion, accompanied with cytoskeleton reorganization, 
thus facilitating cancer cell invasion and metastasis.22 In addition, 
EMT also endows tumor cells with cancer stem cell-like features and 
resistance to senescence and apoptosis.28 For decades, studies have 
elucidated the essential role of the microenvironment on phenotype 
conversion exhibited by cancer cells. Some studies have shown that 
ATP6L promotes migration based on the observation that it induces 
the activation of matrix metalloproteinase (MMP)-2, matrix metal-
loproteinase (MMP)-9 and cathepsin, which take part in ECM deg-
radation and facilitate the escape of tumor cells from the primary 
site.24,29,30 In the present study, the tumor tissue with strong ATP6L 
expression showed lower levels of E-cadherin and higher levels of 
vimentin expression than the tumor tissues with weak or negative 
expression, indicating a mesenchymal-like characteristic similar to 
that in the EMT process. Similar results were also demonstrated 
both in vitro and in mouse model tests, accompanied by actin cyto-
skeleton reprogramming and enhanced motility, further confirming 
that ATP6L can advance the EMT program in CRC. Thus, except in 
ECM degradation, the EMT of cancer cells induced by ATP6L overex-
pression may also contribute to the enhanced migratory and invasive 
abilities of CRC.
In this study, change of proliferation in HT29 and HCT116 cells 
with ectopic ATP6L expression in MTT experiment was not ob-
served. Inconsistent with our results, Ohta et al31 observed that ba-
filomycin A1, a specific inhibitor of ATP6L, could inhibit the growth 
of a variety of cultured pancreatic cancer cells in a dose-dependent 
manner. We propose that the effects of ATP6L on the prolifera-
tion of tumors may be type-dependent and influenced by multiple 
mechanisms.
In the in vitro MTT analysis the proliferation of ATP6L-
overexpressing cells showed no significant differences from the 
control cells, whereas our result in the animal experiment showed 
that ATP6L-overexpressing cells produced larger tumor masses 
than control cells. It has been reported that an acidic extracellular 
F I G U R E  6   Effect of ATP6L 
overexpression on necrosis and 
angiogenesis of harvested mouse tumor. 
A, H&E photographs illustrating necrosis 
in mice tumor tissues derived from ATP6L-
transfected HCT116 cells and control 
cells, 40×. B, Quantitative analysis of 
the proportions of necrotic tissue in the 
largest section of tumor masses is shown 
as mean ± SD. C, Immunohistochemical 
staining for CD34 expression in harvested 
mouse tumor samples, 200×. Black arrows 
point to the microvessels in the tumor
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microenvironment could induce cancer cells to secrete pro– 
angiogenesis factors, such as interleukin-8 and vascular endo-
thelial growth factor; thus, it is beneficial to tumor angiogenesis 
and growth.32,33 Our result that mice tumor tissues derived from 
ATP6L-transfected HCT116 cells illustrated decreased necrosis and 
increased angiogenesis may explain the inconsistency between in 
vitro and in vivo experiments and point out more possible mecha-
nisms of the tumor-promoting effect of ATP6L. A similar result was 
observed in the study of Lu (2005), who found that small RNA inter-
ference of ATP6L can reduce blood supply in hepatocellular carci-
noma mouse xenografts.34 Moreover, tumor neovessels formed by 
loosely and irregularly arranged immature endothelial cells increase 
the chances of the entry of tumor cells into the microcirculation and 
subsequently contribute to distant dissemination. Thus, ATP6L may 
exert its metastasis-promoting effect by inducing EMT of CRC cells 
and promoting angiogenesis.
Cruciat et al35 reported that treating HEK293T cells with siRNA 
targeting ATP6L inhibited Wnt signaling by blocking the phosphor-
ylation and endocytosis of the LRP6 receptor and β-catenin activa-
tion following ligand binding. George et al36 showed that bafilomycin 
A blocks the activation of canonical Wnt signaling. Although these 
studies were performed in nonmalignant cells, all the results sug-
gested that ATP6L is required for the activation of Wnt/β-catenin 
signaling. Especially in CRC, Wnt/β-catenin signaling is simultane-
ously involved in regulating EMT and tumor angiogenesis and is 
crucial in tumorigenesis and progression. Future studies designed to 
elucidate ATP6L expression on other tumor types and its effects on 
canonical Wnt signal pathway are currently in progress.
Collectively, we demonstrated that ATP6L is markedly overex-
pressed in the poorly differentiated CRC tissues evidently located in 
the invasive front and metastatic foci. More importantly, in vitro and 
in vivo data demonstrated that ATP6L can induce the EMT program 
and promote tumor progression in CRC cells. Furthermore, ectopic 
ATP6L expression can promote MVD in animal xenograft tissue. 
These results demonstrate that ATP6L advances the malignant pro-
gression of human CRC intrinsically and externally (Figure 7). The 
co–evolution of cancer cells with the adjacent microenvironment 
determines every step of malignant progression. Thus, eliminating 
cancer cells and manipulating TME should be considered in develop-
ing antitumor therapies. The results of the current study reveal the 
potential of targeting ATP6L for cancer treatment.
ACKNOWLEDG MENTS
This research was funded by the National Natural Science Foundation 
of China (Nos. 81402420, 380 81702161 and 81801781), the Project 
of Tianjin Natural Science Foundation (Nos. 15JCQNJC12400 and 381 
15JCQNJC14500) and the Top talent training program of the first affili-
ated hospital of PLA Army Medical 382 University (SWH2018BJKJ-12).
DISCLOSURE
The authors have no conflict of interest to declare.
ORCID
Chao Zhang  https://orcid.org/0000-0001-7096-8488 
Xin Wang  https://orcid.org/0000-0001-9325-3194 
Lisha Qi  https://orcid.org/0000-0002-8700-4690 
F I G U R E  7   Graphical abstract 
illustrating that ATP6L exert a metastasis-
promoting effect by inducing epithelial-
mesenchymal transition (EMT) of human 
colorectal carcinoma (CRC) cells
488  |     WANG et Al.
R E FE R E N C E S
 1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. 
Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
 2. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, 
Bray F. Global patterns and trends in colorectal cancer incidence 
and mortality. Gut. 2017;66:683-691.
 3. Fakih MG. Metastatic colorectal cancer: current state and future 
directions. J Clin Oncol. 2015;33:1809-1824.
 4. Paget S. The distribution of secondary growths in cancer of the 
breast 1889. Cancer Metastasis Rev. 1989;8:98-101.
 5. Chen Q, Liu G, Liu S, et al. Remodeling the tumor microenvironment 
with emerging nanotherapeutics. Trends Pharmacol Sci. 2018;39:59-74.
 6. Maman S, Witz IP. A history of exploring cancer in context. Nat Rev 
Cancer. 2018;18:359-376.
 7. Liberti MV, Locasale JW. The Warburg effect: how does it benefit 
cancer cells? Trends Biochem Sci. 2016;41:211-218.
 8. Gatenby RA, Gawlinski ET. The glycolytic phenotype in carcino-
genesis and tumor invasion: insights through mathematical models. 
Cancer Res. 2003;63:3847-3854.
 9. Tian XP, Wang CY, Jin XH, et al. Acidic microenvironment up-reg-
ulates exosomal miR-21 and miR-10b in early-stage hepatocellular 
carcinoma to promote cancer cell proliferation and metastasis. 
Theranostics. 2019;9:1965-1979.
 10. Huber V, Camisaschi C, Berzi A, et al. Cancer acidity: an ultimate 
frontier of tumor immune escape and a novel target of immuno-
modulation. Semin Cancer Biol. 2017;43:74-89.
 11. Walenta S, Wetterling M, Lehrke M, et al. High lactate levels predict 
likelihood of metastases, tumor recurrence, and restricted patient 
survival in human cervical cancers. Cancer Res. 2000;60:916-921.
 12. Morita T, Nagaki T, Fukuda I, Okumura K. Clastogenicity of low pH 
to various cultured mammalian cells. Mutat Res. 1992;268:297-305.
 13. Kolosenko I, Avnet S, Baldini N, Viklund J, De Milito A. Therapeutic 
implications of tumor interstitial acidification. Semin Cancer Biol. 
2017;43:119-133.
 14. Stransky L, Cotter K, Forgac M. The function of V-ATPases in can-
cer. Physiol Rev. 2016;96:1071-1091.
 15. Ohta T, Numata M, Yagishita H, et al. Expression of 16 kDa proteo-
lipid of vacuolar-type H(+)-ATPase in human pancreatic cancer. Br J 
Cancer. 1996;73:1511-1517.
 16. Nishisho T, Hata K, Nakanishi M, et al. The a3 isoform vacuolar type 
H⁺-ATPase promotes distant metastasis in the mouse B16 mela-
noma cells. Mol Cancer Res. 2011;9:845-855.
 17. Michel V, Licon-Munoz Y, Trujillo K, Bisoffi M, Parra KJ. Inhibitors of 
vacuolar ATPase proton pumps inhibit human prostate cancer cell 
invasion and prostate-specific antigen expression and secretion. Int 
J Cancer. 2013;132:E1-E10.
 18. Hendrix A, Sormunen R, Westbroek W, et al. Vacuolar H+ ATPase ex-
pression and activity is required for Rab27B-dependent invasive growth 
and metastasis of breast cancer. Int J Cancer. 2013;133:843-854.
 19. Forgac M. Vacuolar ATPases: rotary proton pumps in physiology 
and pathophysiology. Nat Rev Mol Cell Biol. 2007;8:917-929.
 20. Xu J, Xie R, Liu X, et al. Expression and functional role of vacuolar 
H(+)-ATPase in human hepatocellular carcinoma. Carcinogenesis. 
2012;33:2432-2440.
 21. Zhang S, Qi L, Li M, et al. Chemokine CXCL12 and its receptor 
CXCR4 expression are associated with perineural invasion of pros-
tate cancer. J Exp Clin Cancer Res. 2008;27:62.
 22. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell in-
vasion. Cancer Metastasis Rev. 2009;28:15-33.
 23. Lee I, Skinner MA, Guo HB, Sujan A, Pierce M. Expression of the 
vacuolar H+-ATPase 16-kDa subunit results in the Triton X-100-
insoluble aggregation of beta1 integrin and reduction of its cell sur-
face expression. J Biol Chem. 2004;279:53007-53014.
 24. Kubota S, Seyama Y. Overexpression of vacuolar ATPase 16-kDa 
subunit in 10T1/2 fibroblasts enhances invasion with concomi-
tant induction of matrix metalloproteinase-2. Biochem Biophys Res 
Commun. 2000;278:390-394.
 25. Byun YJ, Lee SB, Lee HO, et al. Vacuolar H+ -ATPase c protects glial 
cell death induced by sodium nitroprusside under glutathione-de-
pleted condition. J Cell Biochem. 2011;112:1985-1996.
 26. Cotter K, Capecci J, Sennoune S, et al. Activity of plasma membrane 
V-ATPases is critical for the invasion of MDA-MB231 breast cancer 
cells. J Biol Chem. 2015;290:3680-3692.
 27. Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell. 
2016;166(1):21-45.
 28. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the 
mechanistic link and clinical implications. Nat Rev Clin Oncol. 
2017;14:611-629.
 29. Chung C, Mader CC, Schmitz JC, et al. The vacuolar-ATPase mod-
ulates matrix metalloproteinase isoforms in human pancreatic can-
cer. Lab Invest. 2011;91:732-743.
 30. Kubisch R, Fröhlich T, Arnold GJ, et al. V-ATPase inhibition by 
archazolid leads to lysosomal dysfunction resulting in impaired 
cathepsin B activation in vivo. Int J Cancer. 2014;134:2478-2488.
 31. Ohta T, Arakawa H, Futagami F, et al. Bafilomycin A1 induces apop-
tosis in the human pancreatic cancer cell line Capan-1. J Pathol. 
1998;185:324-330.
 32. Nakanishi M, Morita Y, Hata K, Muragaki Y. Acidic microenviron-
ments induce lymphangiogenesis and IL-8 production via TRPV1 
activation in human lymphatic endothelial cells. Exp Cell Res. 
2016;345:180-189.
 33. Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK. Hypoxia 
and acidosis independently up-regulate vascular endothelial 
growth factor transcription in brain tumors in vivo. Cancer Res. 
2001;61:6020-6024.
 34. Lu X, Qin W, Li J, et al. The growth and metastasis of human hepa-
tocellular carcinoma xenografts are inhibited by small interfering 
RNA targeting to the subunit ATP6L of proton pump. Cancer Res. 
2005;65:6843-6849.
 35. Cruciat CM, Ohkawara B, Acebron SP, et al. Requirement of pro-
renin receptor and vacuolar H+-ATPase-mediated acidification for 
Wnt signaling. Science. 2010;327:459-463.
 36. George A, Leahy H, Zhou J, Morin PJ. The vacuolar-ATPase inhibi-
tor bafilomycin and mutant VPS35 inhibit canonical Wnt signaling. 
Neurobiol Dis. 2007;26:125-133.
How to cite this article: Wang J, Chen D, Song W, et al. 
ATP6L promotes metastasis of colorectal cancer by inducing 
epithelial-mesenchymal transition. Cancer Sci. 2020;111:477–
488. https ://doi.org/10.1111/cas.14283 
